-
公开(公告)号：US20180064716A1
公开(公告)日：2018-03-08
申请号：US15808223
申请日：2017-11-09
Applicant: Lixin Zhang
Inventor： Lixin Zhang
IPC: A61K31/53
CPC classification number: A61K31/53
Abstract: Provided are articles of manufacture, compositions and methods for prophylaxis and/or therapy for disorders involving dizziness and/or vertigo. The articles of manufacture and compositions contain lamotrigen and/or bupropion. The compositions include pharmaceutical compositions which are intended to alleviate dizziness and/or vertigo. In certain aspects the disclosure includes articles of manufacture and kits which include printed material which provides an indication that the articles or compositions are intended to be used for prophylaxis and/or therapy of Meniere's Disease or a symptom thereof.
-
公开(公告)号：US09889137B2
公开(公告)日：2018-02-13
申请号：US15612984
申请日：2017-06-02
Applicant: Agios Pharmaceuticals, Inc.
Inventor： Samuel V. Agresta
IPC: A61K31/53 , A61K9/00 , A61K31/185
CPC classification number: A61K31/53 , A61K9/0053 , A61K31/185
Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).
-
公开(公告)号：US20180008561A1
公开(公告)日：2018-01-11
申请号：US15712026
申请日：2017-09-21
Applicant: ELCELYX THERAPEUTICS, INC.
Inventor： Alain D. BARON , Mark S. FINEMAN , Nigel R. A. BEELEY
IPC: A61K31/155 , A61K9/00 , C07D307/52 , C07D255/02 , C07D251/18 , C07D251/10 , C07D249/14 , A61K45/06 , A61K31/55 , A61K31/53 , A61K31/4196 , A61K31/36 , A61K9/28 , A61K9/20 , C07D317/58 , C07D405/12
CPC classification number: A61K31/155 , A61K9/0053 , A61K9/2054 , A61K9/2813 , A61K9/282 , A61K9/2846 , A61K9/2866 , A61K31/36 , A61K31/4196 , A61K31/53 , A61K31/55 , A61K45/06 , C07D249/14 , C07D251/10 , C07D251/18 , C07D255/02 , C07D307/52 , C07D317/58 , C07D405/12 , A61K2300/00
Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
-
公开(公告)号：US20170368069A1
公开(公告)日：2017-12-28
申请号：US15543228
申请日：2016-01-08
Applicant: Bayer Pharma Aktiengesellschaft
Inventor： Arne SCHOLZ
CPC classification number: A61K31/53 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , A61K2300/00
Abstract: The present invention relates to the use of 4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A), more particularly (+)-4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound A′), for treating leukemias, in particular acute leukemias, preferably acute myeloid leukemias.
-
公开(公告)号：US09845298B1
公开(公告)日：2017-12-19
申请号：US15681270
申请日：2017-08-18
Inventor： Niu Huang , Yu Zhou , Xingyu Lin
IPC: A61K31/53 , C07D251/72 , C07D251/10 , A61K45/06
CPC classification number: C07D251/72 , A61K31/53 , A61K45/06 , C07D251/10
Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.
-
Patent Agency Ranking
公开(公告)号：US20170349559A1
公开(公告)日：2017-12-07
申请号：US15681270
申请日：2017-08-18
Inventor： Niu Huang , Yu Zhou , Xingyu LIN
IPC: C07D251/72 , A61K31/53 , A61K45/06 , C07D251/10
CPC classification number: C07D251/72 , A61K31/53 , A61K45/06 , C07D251/10
Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.
-
公开(公告)号：US20170348319A1
公开(公告)日：2017-12-07
申请号：US15683589
申请日：2017-08-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Stephen Hitchcock , Betty Lam , Holger Monenschein , Holly Reichard
IPC: A61K31/53 , C07D253/08
CPC classification number: A61K31/53 , C07D253/08
Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
-
78.发明申请公开(公告)号：US20170348318A1
公开(公告)日：2017-12-07
申请号：US15630886
申请日：2017-06-22
Applicant: Agios Pharmaceuticals, Inc.
Inventor： Jeremy Travins , Luke Utley
IPC: A61K31/53 , C07D417/12 , C07D413/12 , C07D403/12 , C07D403/04 , C07D401/14 , C07D401/12 , C07D401/04 , C07D251/18 , C07D417/14 , A61K45/06
CPC classification number: A61K31/53 , A61K45/06 , C07D251/18 , C07D251/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D413/12 , C07D417/12 , C07D417/14
Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
-
公开(公告)号：US09833456B2
公开(公告)日：2017-12-05
申请号：US15290513
申请日：2016-10-11
Applicant: Strategic Science & Technologies, LLC
Inventor： Eric T. Fossel
IPC: A61K31/519 , A61K47/22 , A61K47/18 , A61K47/02 , A61K47/26 , A61K47/16 , A61K9/00 , A61K31/53 , A61K31/495 , A61K9/06 , A61K9/107 , A61K31/198 , A61K31/506 , A61K47/36 , A61K31/4985 , A61K47/10
CPC classification number: A61K31/53 , A61K9/0014 , A61K9/0034 , A61K9/06 , A61K9/107 , A61K31/198 , A61K31/495 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/183 , A61K47/22 , A61K47/26 , A61K47/36 , A61K2300/00
Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.
-
80.发明申请公开(公告)号：US20170342049A1
公开(公告)日：2017-11-30
申请号：US15528435
申请日：2015-11-17
Inventor： Thanusha Thatikonda , Suresh Kumar , Umed Singh , Priya Mahajan , Girish Mahajan , Amit Nargotra , Fayaz Malik , Dilip Manikrao Mondhe , Ram Asrey Vishwakarma , Parvinder Pal Singh
IPC: C07D401/04 , A61K31/519 , A61K31/53 , C07D401/14 , A61K39/395
CPC classification number: C07D401/04 , A61K31/519 , A61K31/53 , A61K39/39558 , A61K2300/00 , C07D401/14
Abstract: The present invention describes heterocyclic compounds of general Formula 1 and their method of preparation thereof. The present invention describes general Formula 1 which inhibits phosphoinositide 3-kinase (PI3K) and can be used as the anticancer agents.
-
-
-
-
-
-
-
-
-
Search Results
2981
records
(took 0.034 seconds)
